BioSpace News Archive

Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022

Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022.

March 30, 2022
·
6 min read
Business

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

CureVac N.V. today announced that first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

March 30, 2022
·
7 min read
Drug Development

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

Biogen Inc. (Nasdaq: BIIB) has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration (FDA) for review and approval.

March 30, 2022
·
8 min read
Drug Development

Antios Therapeutics’ ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies

Antios Therapeutics, Inc. today announced new data from the Phase 1b and 2a clinical trials of ATI-2173, its investigational proprietary drug candidate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development for HBV.

March 30, 2022
·
5 min read
Business

UpHealth Announces Fourth Quarter and Full Year 2021 Financial Results

UpHealth, Inc. today announced financial results for the fourth quarter and full year ended Dec. 31, 2021.

March 30, 2022
·
18 min read
Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot

Mapi Pharma Ltd., announced today that the company has been granted U.S. Patent No. 11,167,003 entitled: “Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems.”

March 30, 2022
·
3 min read
Drug Development

Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Prometheus Biosciences, Inc today announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase 2 study of PRA023 in SSc-ILD.

March 30, 2022
·
7 min read
Business

Delfi Diagnostics Appoints Liz Homans to its Board of Directors

Delfi Diagnostics appointed Liz Homans, CEO of Lyell Immunopharma, Inc., to Delfi’s Board of Directors.

March 30, 2022
·
1 min read
Pharm Country

Researchers Discover New Model for “Global” DNA Repair

Two studies provide a radically new picture of how bacterial cells continually repair damaged sections in their DNA.

March 30, 2022
·
5 min read
Novel Innovations Are Taking Place in Transplant Diagnostics Market across the World

There have been huge advancements in technology, in the last few years, in terms of providing top-notch diagnostics options for proper management of organ transplants, which in turn has driven the transplant diagnostics market in more than one way.

March 30, 2022
·
2 min read